Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

-- Two Companies to also Collaborate on the Further Development of Complera®, Marketed as Eviplera® in the European Union --

Janssen R&D Ireland (Janssen) announced today an amendment to its existing agreement with Gilead Sciences, Inc. (Gilead), initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV. This new STR contains a combination of darunavir (PREZISTA®), cobicistat (TYBOST®), emtricitabine and tenofovir alafenamide (TAF). A number of Phase 1 and 2 studies of the new STR have been completed. Under this amended agreement, Janssen will conduct all further clinical development of the regimen and, subject to regulatory approval, will be responsible for all manufacturing, registration, distribution and commercialization of the product worldwide.

If successfully developed and approved by regulatory authorities, this treatment would represent the first protease inhibitor-based STR and thereby continue Janssen's commitment to providing its HIV products in more simplified dosing presentations.

"Janssen has vast experience in developing and making innovative HIV treatments available to patients and we have engaged in several successful collaborations with Gilead. We are proud to be extending our collaboration and leading the development of this darunavir-based single-tablet regimen," says Paul Stoffels, Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. "Our ultimate goal is to offer new treatment options for people living with HIV. If approved, this STR has the potential to provide additional choice in the form of another one pill, once a day, as a new and simplified regimen."

In addition to this collaboration, Janssen and Gilead have also expanded a separate agreement initiated in 2009 regarding the approved single-tablet regimen, COMPLERA®, marketed as EVIPLERA® in the European Union (EU) (rilpivirine, tenofovir disoproxil fumarate (TDF) and emtricitabine). This expanded agreement will allow for Gilead's investigational tenofovir alafenamide (TAF), a novel nucleotide reverse transcriptase inhibitor, to replace TDF within COMPLERA®/ EVIPLERA®. TAF has been shown in clinical trials to have a better renal and bone safety profile than TDF. Gilead will be responsible for the development and commercialization in most countries, while Janssen will lead the commercialization in select markets.

Since the beginning of the HIV epidemic, almost 75 million people have been infected with the HIV virus. It is estimated that 35 million people are currently living with HIV globally, with 2.5 million people becoming newly infected each year.

SOURCE Janssen R&D Ireland Ltd

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
New approach to broadly acting, highly effective HIV vaccine